NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis $45.69 +1.17 (+2.63%) Closing price 04:00 PM EasternExtended Trading$45.80 +0.11 (+0.23%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rigel Pharmaceuticals Stock (NASDAQ:RIGL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rigel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$43.44▼$46.2150-Day Range$39.65▼$51.4552-Week Range$24.95▼$52.60Volume325,687 shsAverage Volume253,705 shsMarket Capitalization$860.34 millionP/E Ratio2.95Dividend YieldN/APrice Target$66.75Consensus RatingHold Company Overview Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation. The company commercializes its products in the United States and has pursued partnerships and licensing arrangements to support the development and availability of its medicines in other markets. Its work spans both internally developed therapies and products obtained through external collaborations.AI Generated. May Contain Errors. Read More Rigel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreRIGL MarketRank™: 4.14535490605 of 5 starsRigel Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 64th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingRigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRigel Pharmaceuticals has a consensus price target of $66.75, representing about 46.1% upside from its current price of $45.69.Amount of Analyst CoverageRigel Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rigel Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth43.77% Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow by 43.77% in the coming year, from $2.97 to $4.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is 2.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is 2.95, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.98.Price to Book Value per Share RatioRigel Pharmaceuticals has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.31% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 12.93, which indicates bearish sentiment.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently decreased by 7.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.05 News SentimentRigel Pharmaceuticals has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest5 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.47% of the stock of Rigel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rigel Pharmaceuticals' insider trading history. Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RIGL Stock News HeadlinesHC Wainwright Has Negative Opinion of RIGL FY2026 EarningsNovember 12 at 1:28 AM | americanbankingnews.comRigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Expected to Rise, Citigroup Analyst SaysNovember 11 at 2:48 AM | americanbankingnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 12 at 1:00 AM | Base Camp Trading (Ad)Rigel Pharmaceuticals: Top-Line Momentum Meets Margin Compression In Q3November 10 at 8:31 AM | seekingalpha.comRigel to Present at the Jefferies Global Healthcare Conference in LondonNovember 10 at 8:05 AM | prnewswire.comRigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $47.00November 9 at 2:30 AM | americanbankingnews.comQ4 EPS Forecast for Rigel Pharmaceuticals Reduced by AnalystNovember 9 at 1:29 AM | americanbankingnews.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Down After Earnings MissNovember 8, 2026 | americanbankingnews.comSee More Headlines RIGL Stock Analysis - Frequently Asked Questions How have RIGL shares performed this year? Rigel Pharmaceuticals' stock was trading at $42.83 on January 1st, 2026. Since then, RIGL stock has increased by 6.7% and is now trading at $45.69. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by $0.27. The biotechnology company earned $80.89 million during the quarter, compared to analysts' expectations of $80.00 million. Rigel Pharmaceuticals had a net margin of 106.59% and a trailing twelve-month return on equity of 14.89%. Read the conference call transcript. When did Rigel Pharmaceuticals' stock split? Rigel Pharmaceuticals shares reverse split before market open on Thursday, June 27th 2024.The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Rigel Pharmaceuticals' major shareholders? Top institutional investors of Rigel Pharmaceuticals include State Street Corp (4.67%), Assenagon Asset Management S.A. (2.90%), Ritholtz Wealth Management (0.58%) and First Trust Advisors LP (0.53%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno, David A Santos, Walter H Moos and Kamil Ali-Jackson. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Novavax (NVAX), Plug Power (PLUG), NIO (NIO) and Vaxart (VXRT). Company Calendar Last Earnings11/05/2026Today11/12/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RIGL's financial health is in the Green zone, according to TradeSmith. RIGL has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees174Year Founded1996Price Target and Rating Average Price Target for Rigel Pharmaceuticals$66.75 High Price Target$86.00 Low Price Target$47.00 Potential Upside/Downside+46.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$15.51 Trailing P/E Ratio2.95 Forward P/E Ratio10.70 P/E GrowthN/ANet Income$367.02 million Net Margins106.59% Pretax Margin26.15% Return on Equity14.89% Return on Assets11.99% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio1.79 Sales & Book Value Annual Sales$294.28 million Price / Sales2.92 Cash Flow$6.92 per share Price / Cash Flow6.60 Book Value$23.64 per share Price / Book1.93Miscellaneous Outstanding Shares18,830,000Free Float16,858,000Market Cap$860.34 million OptionableOptionable Beta1.28 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:RIGL) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | SponsoredProfessor Who Lectured at Harvard Warns: Sell These 10 Stocks Before Dec. 10Joel Litman, a professor who has lectured at Harvard and Wharton, is warning of a $33 trillion grid crisis tha...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
